{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:28:56Z","timestamp":1792193336930,"version":"4.4.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Digestive and Liver Disease"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1016\/j.dld.2012.04.013","type":"journal-article","created":{"date-parts":[[2012,5,30]],"date-time":"2012-05-30T18:46:55Z","timestamp":1338403615000},"page":"803-811","source":"Crossref","is-referenced-by-count":8,"title":["Chemotherapy in the treatment of anal canal carcinoma"],"prefix":"10.1016","volume":"44","author":[{"given":"Wulfran","family":"Cacheux","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Astrid","family":"Lievre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"De La Rochefordiere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Dieumegard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Cvitkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Labib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Mitry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Buecher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dld.2012.04.013_bib0005","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(96)03409-5","article-title":"Epidermoid anal cancer: results from the UKCCCR randomized trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin C","volume":"348","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2012.04.013_bib0010","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/sj.bjc.6605605","article-title":"Chemotherapy for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomized UKCCCR anal cancer trial","volume":"102","author":"Northover","year":"2010","journal-title":"British Journal of Cancer"},{"key":"10.1016\/j.dld.2012.04.013_bib0015","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","volume":"15","author":"Bartelink","year":"1997","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.dld.2012.04.013_bib0020","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.1996.14.9.2527","article-title":"Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive non surgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study","volume":"14","author":"Flam","year":"1996","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.dld.2012.04.013_bib0025","series-title":"Proc. ASCO","first-page":"989","article-title":"5-Year results and analyses of a phase III randomized RTOG\/ECOG chemoradiation protocol for anal cancer","author":"John","year":"1998"},{"key":"10.1016\/j.dld.2012.04.013_bib0030","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/0360-3016(91)90265-6","article-title":"Epidermoid anal cancer: treatment by radiation alone or by radiation and 5-FU with and without mitomycin C","volume":"21","author":"Cummings","year":"1991","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.dld.2012.04.013_bib0035","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/0167-8140(93)90076-K","article-title":"Chemoradiation therapy for anal cancer: radiation plus continuous infusion of fluorouracil with or without cisplatin","volume":"27","author":"Rich","year":"1993","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.dld.2012.04.013_bib0040","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0167-8140(97)00192-8","article-title":"Treatment of anal carcinoma with high-dose radiation and concomitant fluorouracil\u2013cisplatin: long-term results in 95 patients","volume":"46","author":"Gerard","year":"1998","journal-title":"Radiotherapy and Oncology"},{"key":"10.1016\/j.dld.2012.04.013_bib0045","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/0360-3016(96)00146-0","article-title":"Initial results of a phase II trial of high-dose radiation therapy, fluorouracil and cisplatin for patients with anal cancer (E4292): an Eastern Cooperative Group Study","volume":"35","author":"Martenson","year":"1996","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.dld.2012.04.013_bib0050","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","article-title":"Fluorouracil, mitomycin, and radiotherapy vs. fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal. A randomized controlled trial","volume":"299","author":"Ajani","year":"2008","journal-title":"Journal of the American Medical Association"},{"issue":"Suppl","key":"10.1016\/j.dld.2012.04.013_bib0055","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1200\/jco.2011.29.15_suppl.4005","article-title":"Long-term update of U.S GI intergroup RTOG 98-11 phase III trial for anal carcinoma: disease-free and overall survival with RT+5 FU-mitomycin versus RT+5 FU-cisplatin","volume":"29","author":"Gunderson","year":"2011","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl.","key":"10.1016\/j.dld.2012.04.013_bib0060","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1200\/jco.2009.27.18_suppl.lba4009","article-title":"A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin\/5 FU in squamous cell carcinoma of the anus (ACTII)","volume":"27","author":"James","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.dld.2012.04.013_bib0065","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0959-8049(02)00377-5","volume":"39","author":"Bosset","year":"2003","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.dld.2012.04.013_bib0070","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.1016\/j.ejca.2009.06.020","article-title":"Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014)","volume":"45","author":"Matzinger","year":"2009","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.dld.2012.04.013_bib0075","first-page":"1045","article-title":"Chemoradiation and maintenance chemotherapy for patients with anal carcinoma: a phase II trial of the UK-coordinating committee for cancer research (UKCCCR) anal cancer trial working party","volume":"19","author":"James","year":"2000","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.dld.2012.04.013_bib0080","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1056\/NEJMoa073149","article-title":"Capecitabine and oxaliplatin for advanced esophagogastric cancer","volume":"358","author":"Cunningham","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.dld.2012.04.013_bib0085","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1533-0028(11)70105-0","article-title":"Efficacy of adjuvant capecitabine compared with bolus 5-fluorouracil\/leucovorin regimen in Dukes C colon cancer: results from the X-ACT trial","volume":"4","author":"Reddy","year":"2004","journal-title":"Clinical Colorectal Cancer"},{"key":"10.1016\/j.dld.2012.04.013_bib0090","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0959-8049(00)00444-5","article-title":"Capecitabine (Xeloda) improves medical resource use compared with 5-fluorouracil plus leucovorin in a phase III trial conducted in patients with advanced colorectal carcinoma","volume":"37","author":"Twelves","year":"2001","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.dld.2012.04.013_bib0095","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ijrobp.2007.12.012","article-title":"EXTRA\u2014a multicenter phase II study of chemoradiation using a 5 day per week oral regimen of capecitabine and intravenous mitomycin C in anal cancer","volume":"72","author":"Glynne-Jones","year":"2008","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"Suppl.","key":"10.1016\/j.dld.2012.04.013_bib0100","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1200\/jco.2009.27.15_suppl.4116","article-title":"Phase II study of capecitabine and oxaliplatin with concurrent radiation therapy (XELOX-RT) for squamous cell carcinoma of the anal canal","volume":"27","author":"Eng","year":"2009","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl.","key":"10.1016\/j.dld.2012.04.013_bib0105","doi-asserted-by":"crossref","first-page":"4033","DOI":"10.1200\/jco.2009.27.15_suppl.4033","article-title":"Treatment intensification by induction chemotherapy (ICT) and radiation dose escalation in locally advanced squamous cell anal canal carcinoma (LAAC): definitive analysis of the ACCORD 03 trial","volume":"27","author":"Conroy","year":"2009","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.dld.2012.04.013_bib0110","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1200\/JCO.2010.29.1351","article-title":"Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of radiation therapy oncology group trials 87-04 and 98-11","volume":"28","author":"Ben-Josef","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.dld.2012.04.013_bib0115","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/S1470-2045(02)00906-3","article-title":"Radiotherapy for cancer of the head and neck: altered fractionation regimens","volume":"2","author":"Nguyen","year":"2002","journal-title":"Lancet Oncology"},{"key":"10.1016\/j.dld.2012.04.013_bib0120","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0140-6736(06)69121-6","article-title":"Hyperfractionated or accelerated radiotherapy in head and neck cancer: A meta-analysis","volume":"368","author":"Bourhis","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.dld.2012.04.013_bib0125","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0360-3016(93)90522-W","article-title":"Overall treatment time in advanced cervical carcinomas: a critical parameter in treatment outcome","volume":"27","author":"Girinsky","year":"1993","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"key":"10.1016\/j.dld.2012.04.013_bib0130","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0360-3016(93)90058-4","article-title":"The influence of treatment time on outcome for squamous cell cancer of the uterine cervix treated with radiation: a patterns-of-care study","volume":"25","author":"Lanciano","year":"1993","journal-title":"International Journal of Radiation Oncology, Biology, Physics"},{"issue":"Suppl.","key":"10.1016\/j.dld.2012.04.013_bib0135","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1200\/jco.2011.29.15_suppl.4098","article-title":"Cetuximab plus radiochemotherapy in locally advanced anal cancer: interim results of the French multicenter phase II trial ACCORD 16","volume":"29","author":"Deutsch","year":"2011","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.dld.2012.04.013_bib0140","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1200\/JCO.2004.00.1792","article-title":"Concurrent cetuximab, cisplatin and concomitant boost radiotherapy for locally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined modality paradigm","volume":"24","author":"Pfister","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.dld.2012.04.013_bib0145","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/cncr.20364","article-title":"Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973\u20132000","volume":"101","author":"Johnson","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.dld.2012.04.013_bib0150","first-page":"861","article-title":"5-Fluorouracile and cisplatinum combination chemotherapy for metastatic squamous-cell anal cancer","volume":"86","author":"Faivre","year":"1999","journal-title":"Bull Cancer"},{"key":"10.1016\/j.dld.2012.04.013_bib0155","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/BF00263905","article-title":"Phase II study of combination bleomycin, vincristine and high-dose methotrexate (BOM) with leucovorin rescue in advanced squamous cell carcinoma of the anal canal","volume":"15","author":"Wilking","year":"1985","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1016\/j.dld.2012.04.013_bib0160","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10637-006-7667-x","article-title":"Phase II study of mitomycin-C, adriamycin, cisplatin (MAP) and bleomycin-CCNU in patients with advanced cancer of the anal canal: an eastern cooperative oncology group study E7282","volume":"24","author":"Jhawer","year":"2006","journal-title":"Investigational New Drugs"},{"key":"10.1016\/j.dld.2012.04.013_bib0165","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1002\/1097-0142(20010801)92:3<642::AID-CNCR1365>3.0.CO;2-Z","article-title":"Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas: results of a Phase II trial","volume":"92","author":"Hainsworth","year":"2001","journal-title":"Cancer"},{"key":"10.1016\/j.dld.2012.04.013_bib0170","series-title":"ASCO GI cancer symposium","first-page":"352","article-title":"The treatment of metastatic squamous cell carcinoma of the anal canal: a single institution experience","author":"Pathak","year":"2008"},{"key":"10.1016\/j.dld.2012.04.013_bib0175","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/125467","article-title":"The role of EGFR inhibitors in the treatment of metastatic anal canal carcinoma: a case series","author":"Saif","year":"2011","journal-title":"Journal of Oncology"},{"key":"10.1016\/j.dld.2012.04.013_bib0180","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000259615","article-title":"Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status","volume":"77","author":"Lukan","year":"2009","journal-title":"Oncology"},{"key":"10.1016\/j.dld.2012.04.013_bib0185","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s10350-006-0786-9","article-title":"Evidence of clinical activity for cetuximab combined with irinotecan in a patient with refractory anal canal squamous-cell carcinoma: report of a case","volume":"50","author":"Phan","year":"2007","journal-title":"Diseases of the Colon and Rectum"},{"issue":"Suppl. 5","key":"10.1016\/j.dld.2012.04.013_bib0190","doi-asserted-by":"crossref","first-page":"v87","DOI":"10.1093\/annonc\/mdq171","article-title":"Anal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Glynne-Jones","year":"2010","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.dld.2012.04.013_bib0195","doi-asserted-by":"crossref","first-page":"106","DOI":"10.6004\/jnccn.2010.0007","article-title":"NCCN clinical practice guidelines in oncology. Anal carcinoma","volume":"8","author":"Engstrom","year":"2010","journal-title":"Journal of the National Comprehensive Cancer Network"}],"container-title":["Digestive and Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865812001533?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1590865812001533?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,1,16]],"date-time":"2022-01-16T13:34:07Z","timestamp":1642340047000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1590865812001533"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":39,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["S1590865812001533"],"URL":"https:\/\/doi.org\/10.1016\/j.dld.2012.04.013","relation":{},"ISSN":["1590-8658"],"issn-type":[{"value":"1590-8658","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}